Domestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the expiry of Boehringer Ingelheim's patent on March 11. This will make diabetes therapy more accessible and cost-effective for millions of people. Companies like Mankind Pharma, Torrent, Alkem, Dr Reddy's, and Lupin will offer Empagliflozin at significantly lower prices.
